Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

N Firouzabadi, P Ghasemiyeh, F Moradishooli… - International …, 2023 - Elsevier
It has been more than three years since the first emergence of coronavirus disease 2019
(COVID-19) and millions of lives have been taken to date. Like most pandemics caused by …

[HTML][HTML] Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines

MR Zinatizadeh, PK Zarandi, M Zinatizadeh… - Biomedicine & …, 2022 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) has a devastating impact on global
populations triggered by a highly infectious viral sickness, produced by the severe acute …

An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in …

K Tabynov, M Solomadin, N Turebekov, M Babayeva… - Scientific reports, 2023 - nature.com
We developed a novel intranasal SARS-CoV-2 subunit vaccine called NARUVAX-C19/Nano
based on the spike protein receptor-binding domain (RBD) entrapped in mannose …

First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune …

DV Parums - … science monitor: international medical journal of …, 2022 - pmc.ncbi.nlm.nih.gov
The Nuvaxovid™(NVX-CoV2373) Novavax vaccine is a recombinant spike (S) protein
nanoparticle vaccine combined with the Matrix-M adjuvant. On December 20, 2021, the …

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26. COV2. S vaccines

GF Zhang, W Meng, L Chen, L Ding… - Journal of Medical …, 2022 - Wiley Online Library
SARS‐CoV‐2 vaccines have contributed to the control of COVID‐19 in some parts of the
world. However, the constant emergence of variants of concern (VOCs) challenges the …

A review on immunological responses to SARS-CoV-2 and various COVID-19 vaccine regimens

S Upreti, M Samant - Pharmaceutical Research, 2022 - Springer
The transmission of SARS-CoV-2 has caused serious health crises globally. So far, 7
vaccines that are already being assessed in Phase IV clinical trials are, Comirnaty/Pfizer; …

SARS-CoV-2: Pathogenesis, therapeutics, variants, and vaccines

X Li, Z Mi, Z Liu, P Rong - Frontiers in Microbiology, 2024 - frontiersin.org
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged in December 2019 with staggering economic fallout …

Vaccines for the Elderly and Vaccination Programs in Europe and the United States

C Anastassopoulou, S Ferous, S Medić, N Siafakas… - Vaccines, 2024 - mdpi.com
The share of the elderly population is growing worldwide as life expectancy increases.
Immunosenescence and comorbidities increase infectious diseases' morbidity and mortality …

[HTML][HTML] From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era

G Miao, Z Chen, H Cao, W Wu, X Chu, H Liu… - Biomedicine & …, 2023 - Elsevier
The COVID-19 pandemic has affected millions of people and posed an unprecedented
burden on healthcare systems and economies worldwide since the outbreak of the COVID …

[HTML][HTML] Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: a nationwide test-negative matched case-control …

R Suphanchaimat, N Nittayasoot, C Jiraphongsa… - Vaccines, 2022 - mdpi.com
The objective of this study is to explore the real-world effectiveness of various vaccine
regimens to tackle the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS …